Could Axsome Therapeutics Turn $5,000 Into $50,000 by 2035?

Axsome Therapeutics has crushed the market since 2021. The company's leading product remains promising, and its pipeline is strong.

The Motley Fool • 3 hours ago

Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility

Axsome Therapeutics (AXSM -1.29%) primarily discovers, develops, and exclusively commercializes innovative medical treatments targeting numerous central nervous system disorders domestically.

The Motley Fool • Oct 28, 2026

Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should Know

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 26, 2026

2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks)

Axsome Therapeutics should expand its approved lineup while not facing the threat of generic competition through 2036. Eli Lilly is a leader in its core market and could diversify its lineup over the long run.

The Motley Fool • Oct 23, 2026

Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?

AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.

Zacks Investment Research • Oct 21, 2026

Top 3 Health Care Stocks That Could Blast Off In October

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga • Oct 21, 2026

Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's?

Axsome sees at least $8 billion in potential peak Auvelity sales. Additional drugs and pipeline candidates could fuel long-term growth.

The Motley Fool • Oct 12, 2026

4 CNS Drug Stocks Worth Watching This World Mental Health Day

AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.

Zacks Investment Research • Oct 9, 2026

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2

NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2026 on Monday, November 2, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.

GlobeNewsWire • Oct 7, 2026

Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?

Axsome Therapeutics is seeing massive revenue growth as it expands its footprint in the central nervous system treatment market. Moderna is moving beyond its pandemic roots by advancing a deep pipeline of mRNA-based vaccines and oncology therapies.

The Motley Fool • Oct 8, 2026